Join
Live feed
·
PRReleasevia Quantisnow
Aligos Therapeutics Inc. logo

Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China

ByQuantisnow·Wall Street's wire, on your screen.
ALGS· Aligos Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ALGS (Aligos Therapeutics Inc.) and more on Quantisnow.